Shenmayizhi Formula Combined with Ginkgo Extract Tablets for the Treatment of Vascular Dementia: A Randomized, Double-Blind, Controlled Trial

Abstract EN

Shenmayizhi formula (SMYZF) has been shown to have an effect on vascular dementia (VaD) in previous studies.

The aim of this study was to evaluate whether a combination of SMYZF with Ginkgo extract tablets improves mild-to-moderate VaD.

In this 12-week, randomized, double-blind, controlled study, we randomly assigned 196 patients with VaD (aged 50–85 years) to either the SMYZF group (n = 98) or the Ginkgo group (n = 98).

All patients received Ginkgo extract tablets as a basic treatment, while the SMYZF group also received SMYZF treatment.

We evaluated the participants at baseline and after 12 weeks of the intervention for the following: the Mini-Mental State Examination (MMSE), National Institutes of Health Stroke Scale (NIHSS), activities of daily living (ADL), Chinese Medicine Symptom Scale (CM-SS) scores, serum endothelin-1 (ET-1), nitric oxide (NO), vascular endothelial growth factor (VEGF), von Willebrand factor (vWF), neuron-specific enolase (NSE), brain-derived neurotrophic factor (BDNF), and homocysteine (Hcy) serum levels.

Both interventions significantly increased MMSE scores and decreased NIHSS, ADL, and CM-SS scores.

The SMYZF group showed greater improvement in MMSE, NIHSS, and CM-SS scores.

Both groups showed a significant decrease in serum ET-1 and an increase in serum VEGF.

Furthermore, serum NO increased, and vWF decreased significantly in the SMYZF group.

Changes in serum ET-1 and NO were greater in the SMYZF group.

Both groups showed a significant increase in serum BDNF and a decrease in serum NSE and Hcy.

Improvement in serum NSE and BDNF was greater in the SMYZF group.

SMYZF combined with Ginkgo extract tablets improved vascular endothelial and cognitive functions, as well as the syndromes diagnosed based on the traditional Chinese medicine in patients with VaD.